

**AMENDED CLAIMS**

**[Received by the International Bureau on 23 September 2004 (23.09.2004):  
original claims 1 - 8 replaced by amended claims 1-28 (4 pages)]**

1. A method for treating cognitive impairment, the method comprising a step of:  
5 providing to a patient in need thereof an amount of one or more selective dopamine D1-like receptor agonists effective for treating the cognitive impairment using a dosing regimen that minimizes side effects and/or desensitization or tolerance to the treatment and/or provides for long term improvement in cognitive function and/or prevention of further deterioration of cognitive function.
- 10 2. The method of Claim 1, further comprising a step of:  
improving other symptoms related to an underlying disease or cause of the cognitive impairment.
- 15 3. The method of Claim 1, further comprising a step of:  
combining the selective dopamine D1-like receptor agonist with a second drug having some efficacy for treating an underlying disease or cause of the cognitive impairment.
- 20 4. The method of Claim 3, wherein the second drug is a selective dopamine D2 receptor agonist.
5. The method of Claim 4, wherein the selective dopamine D2 receptor agonist is haloperidol.
- 25 6. The method of Claim 3, wherein the combination of the selective dopamine D1-like receptor agonist and the second drug acts additively or synergistically.
7. The method of Claim 1, wherein the selective dopamine D1-like receptor agonist is  
30 DAS-431.
8. A method for generating a profile for correlating dopaminergic state to cognitive impairment, the method comprising steps of:

determining a dopaminergic status and/or cognitive function of both individual  
35 patients with cognitive impairment and of a population of patients with cognitive  
impairment associated with a particular disease state or normal aging process; and  
correlating the dopaminergic status and/or the cognitive function both in the  
individual patient and in the particular population of patients.

40 9. (new) Use of one or more selective dopamine D1-like receptor agonist for the  
preparation of a pharmaceutical pack or kit for the treatment of cognitive impairment.

10. (new) Use of one or more selective dopamine D1-like receptor agonist and a  
selective dopamine D2 receptor agonist for the preparation of a pharmaceutical pack or kit  
45 for the treatment of cognitive impairment.

11. (new) The use according to Claim 10 or Claim 11, wherein said dopamine D1-like  
receptor agonist comprises DAS-431.

50 12. (new) The use according to Claim 10 or Claim 11, wherein said selective dopamine  
D2 receptor agonist comprises haloperidol.

13. (new) A pharmaceutical pack or kit for the treatment of cognitive impairment  
comprising one or more selective dopamine D1-like receptor agonist

55

14. (new) A pharmaceutical pack or kit for the treatment of cognitive impairment  
comprising one or more selective dopamine D1-like receptor agonist and a selective  
dopamine D2 receptor agonist.

60 15. (new) The pharmaceutical pack or kit according to Claim 13 or Claim 14, wherein  
said dopamine D1-like receptor agonist comprises DAS-431.

16. (new) The pharmaceutical pack or kit according to Claim 14 or Claim 15, wherein  
said selective dopamine D2 receptor agonist comprises haloperidol.

65

17. (new) A composition comprising one or more selective dopamine D1-like receptor agonist and a pharmaceutically acceptable carrier or excipient for use as medicament for the treatment of cognitive impairment.
- 70 18. (new) A composition comprising one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist in a pharmaceutically acceptable carrier or excipient for use as medicament for the treatment of cognitive impairment.
- 75 19. (new) The composition according to Claim 17 or Claim 18, wherein said selective dopaminic D1-like receptor agonist comprises DAS-431.
20. (new) The composition according to Claim 18 or Claim 19, wherein said selective dopamine D2 receptor agonist comprises haloperidol.
- 80 21. (new) Use of one or more selective dopaminic D1-like receptor agonist for the preparation of a medicament for the treatment of cognitive impairment.
- 85 22. (new) Use of one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist for the preparation of a medicament for the treatment of cognitive impairment.
23. (new) The use according to Claim 21 or Claim 22, wherein said dopamine D1-like receptor agonist comprises DAS-431.
- 90 24. (new) The use according to Claim 22 or Claim 23, wherein said selective dopamine D2 receptor agonist comprises haloperidol.
- 95 25. (new) The use according to Claim 21, wherein the medicament comprises one or more selective dopamine D1-like receptor agonist receptor ligand and a pharmaceutically acceptable carrier or excipient.

26. (new) The use according to Claim 22, wherein the medicament comprises one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist and a pharmaceutically acceptable carrier or excipient.

100 27. (new) The use according to Claim 25 or Claim 26, wherein said dopamine D1-like receptor agonist comprises DAS-431.

28. (new) The use according to Claim 26 or Claim 27, wherein said selective dopamine D2 receptor agonist comprises haloperidol.

105

**STATEMENT UNDER**  
**ARTICLE 19(1)**

The claims have been amended to add European format claims. The amended claims find support in the description and drawings as filed and do not introduce any new matter.